NCBiotech News

The University of North Carolina at Chapel Hill and BASF Corporation are joining forces to address global challenges.

Syngenta has donated four custom plant growth chambers valued at $1.5 million to NC State's Plant Sciences Initiative.

RTP medical device company TransEnterix is establishing the first Asia-Pacific training center for its Senhance Surgical System at the Saitama Medical University International Center in Tokyo.

Biogen announces a $250 million, 20-year initiative – Healthy Climate, Healthy Lives – to eliminate fossil fuel emissions across all its operations by 2040.

Getting accurate, timely information on COVID-19 cases is one of the major challenges facing policymakers as they make decisions about public health and the economy. Researchers at North Carolina State University are embarking on a project aimed at making sure test kits are available where they are most needed, so that policymakers have the information they need.

The innovative California-based cancer-detection company GRAIL, Inc., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public.

Raleigh-based AgEye Technologies, which typically provides its indoor farming customers AI-powered cameras, sensors and predictive analytics, has added its pandemic-beating “plant scientist in a box” to its portfolio.

A researcher in the Brody School of Medicine at East Carolina University is using an NCBiotech grant to study the human and environmental safety of NoPest, an ECU-created novel pesticide aimed at mosquito control.

Burlington-based LabCorp has developed the first testing method to simultaneously detect for COVID-19, influenza A / B, and respiratory syncytial virus (RSV) just in time for the upcoming flu season.

RedHill Biopharma, an Israeli company with U.S. headquarters in Raleigh, says one of its drug candidates, opaganib, completely inhibited the replication of the coronavirus that causes COVID-19 in a laboratory study.

Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.

GeneCoda executive Don Alexander shares results of a 100-company survey his team conducted to understand the COVID-19 impact on life sciences businesses.

RTI International and Duke University’s Human Vaccine Institute will collaborate in a global project to identify viruses and other pathogens in wildlife that could cause disease in people, such as the coronavirus responsible for the COVID-19 pandemic

Durham’s BioCryst Pharmaceuticals has landed a new federal contract totaling $44 million and added some $3 million to an existing contract to support the development of galidesivir as a possible COVID-19 treatment.

bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.